Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response

• Status: Not yet recruiting
• Trial end date: 0000-00-00
• Target enrollment: 60
• Participant gender: All

Summary

This is a 6-month open-label, randomized control trial in adults to find out if certain neuromarkers can predict individual treatment response to stimulant medications for Attention Deficit Hyperactivity Disorder (ADHD). Males and females, ages 18-55, will be randomized to receive either an amphetamine or a methylphenidate formulation for their ADHD. Before beginning to receive medication treatment, each subject will complete an MRI scan at MIT.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Massachusetts Institute of Technology
• Treatments: Adderall; Amphetamine; Methylphenidate
• Last Updated: 2017-05-15

Criteria

Inclusion Criteria:

• Male and female adults ages 18-55

• A diagnosis of DSM-V ADHD based on clinical assessment supported by the ADHD module of a structured diagnostic interview

• Proficiency in English

• Right-handed

Exclusion Criteria:

• Any contraindication for the use of a stimulant medication

• Investigator and his/her immediate family (spouse, parent, child, grandparent, or grandchild)

• Any contraindications for MRI examination (metallic implants, such as pacemakers, surgical aneurysm clips, or known metal fragments in the body)

• Women who are currently pregnant or breastfeeding, as confirmed by a urine pregnancy test

• Clinically significant abnormal baseline laboratory values, including systolic and diastolic blood pressure parameters above 140 and 90, respectively and resting heart rate outside 60-100 bpm